An Update on Angiogenesis Targeting in Head and Neck Squamous Cell Carcinoma

Overview

Journal Cancers Head Neck

Publisher Biomed Central

Date 2020 Apr 14

PMID 32280512

Citations 27

Authors

Ida Micaily

Jennifer Johnson

Athanassios Argiris

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is an integral aspect of the growth and proliferation of solid tumors, including head and neck squamous cell carcinoma (HNSCC), and has potential implications in prognosis and treatment of both localized and recurrent/metastatic HNSCC. Therefore, there has been a significant interest in utilizing anti-angiogenic agents either alone or in combination with currently approved and emerging therapies. A phase III randomized trial (E1305) of chemotherapy with or without bevacizumab in the first-line treatment of recurrent/metastatic HNSCC showed an increased response rate and longer progression-free survival but fell short in demonstrating a statistically significant improved survival with bevacizumab. Moreover, toxicity, especially bleeding, was increased. Nevertheless, the study of other anti-angiogenic agents and novel combinations with other therapies, including immunotherapy, remains of interest. Several clinical trials are currently underway.

Citing Articles

Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors.

Su Y, Ouchi R, Daroonpan P, Hamagaki M, Ikeda T, Rika N Cancer Immunol Immunother. 2025; 74(4):130.

PMID: 40025278 PMC: 11872838. DOI: 10.1007/s00262-025-03982-9.

Profiling the Tumor Immune Microenvironment of HPV-Associated Base of Tongue Squamous Cell Carcinoma.

Alahmadi R, Awadalla M, Marraiki N, Alswayyed M, Alshehri H, Alsahli A Onco Targets Ther. 2025; 18:263-281.

PMID: 39995441 PMC: 11849419. DOI: 10.2147/OTT.S505376.

Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer Model.

Huang B, Li F, Su S, Chen C, Chang K, Yang M J Cell Mol Med. 2025; 29(1):e70324.

PMID: 39757131 PMC: 11702377. DOI: 10.1111/jcmm.70324.

Clinical implications of activation of the LIMD1-VHL-HIF1α pathway during head-&-neck squamous cell carcinoma development.

Mukhopadhyay D, Chakraborty B, Sarkar S, Alam N, Panda C Indian J Med Res. 2024; 159(5):479-493.

PMID: 39382421 PMC: 11463245. DOI: 10.25259/ijmr_1262_22.

Advanced Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies.

Park R, Chung C Mol Cancer Ther. 2024; 23(12):1717-1730.

PMID: 39301607 PMC: 11612620. DOI: 10.1158/1535-7163.MCT-24-0281.

References

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Hsu H, Wall N, Hsueh C, Kim S, Ferris R, Chen C . Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 2013; 50(1):19-26. DOI: 10.1016/j.oraloncology.2013.10.003. View

Fury M, Xiao H, Sherman E, Baxi S, Smith-Marrone S, Schupak K . Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2015; 38 Suppl 1:E566-70. PMC: 5398410. DOI: 10.1002/hed.24041. View

Kyzas P, Cunha I, Ioannidis J . Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005; 11(4):1434-40. DOI: 10.1158/1078-0432.CCR-04-1870. View

Rini B, Powles T, Atkins M, Escudier B, Mcdermott D, Suarez C . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019; 393(10189):2404-2415. DOI: 10.1016/S0140-6736(19)30723-8. View

Hoang T, Huang S, Armstrong E, Eickhoff J, Harari P . Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res. 2012; 31:37. PMC: 3537546. DOI: 10.1186/1756-9966-31-37. View

Swiecicki P, Zhao L, Belile E, Sacco A, Chepeha D, Dobrosotskaya I . A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Invest New Drugs. 2015; 33(6):1248-56. DOI: 10.1007/s10637-015-0293-8. View

Argiris A, Bauman J, Ohr J, Gooding W, Heron D, Duvvuri U . Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol. 2016; 27(8):1594-600. PMC: 6279075. DOI: 10.1093/annonc/mdw204. View

Polanska H, Raudenska M, Hudcova K, Gumulec J, Svobodova M, Heger Z . Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients. Oncol Lett. 2016; 12(3):2127-2132. PMC: 4998659. DOI: 10.3892/ol.2016.4896. View

10.

Vassilakopoulou M, Psyrri A, Argiris A . Targeting angiogenesis in head and neck cancer. Oral Oncol. 2015; 51(5):409-15. DOI: 10.1016/j.oraloncology.2015.01.006. View

11.

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

12.

Taylor M, Lee C, Makker V, Rasco D, Dutcus C, Wu J . Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020; 38(11):1154-1163. PMC: 7145588. DOI: 10.1200/JCO.19.01598. View

13.

Argiris A, Li S, Savvides P, Ohr J, Gilbert J, Levine M . Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. J Clin Oncol. 2019; 37(34):3266-3274. PMC: 6980834. DOI: 10.1200/JCO.19.00555. View

14.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

15.

Elser C, Siu L, Winquist E, Agulnik M, Pond G, Chin S . Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007; 25(24):3766-73. DOI: 10.1200/JCO.2006.10.2871. View

16.

Limaye S, Riley S, Zhao S, ONeill A, Posner M, Adkins D . A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013; 49(8):835-41. DOI: 10.1016/j.oraloncology.2013.04.010. View

17.

Kalyankrishna S, Grandis J . Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24(17):2666-72. DOI: 10.1200/JCO.2005.04.8306. View

18.

Hainsworth J, Spigel D, Greco F, Shipley D, Peyton J, Rubin M . Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011; 17(5):267-72. DOI: 10.1097/PPO.0b013e3182329791. View

19.

Choong N, Kozloff M, Taber D, Hu H, Wade 3rd J, Ivy P . Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2009; 28(5):677-83. DOI: 10.1007/s10637-009-9296-7. View

20.

Vermorken J, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F . Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to.... J Clin Oncol. 2007; 25(16):2171-7. DOI: 10.1200/JCO.2006.06.7447. View